Icon and DuPage Medical forge clinical research partnership


Share

icon-dupageIcon recently announced that its PMG Research and DuPage Medical Group have signed a clinical research partnership. Starting this month, PMG Research will serve as the research infrastructure at DuPage Medical.

The partnership will help expand PMG Research’s network to help Icon have more access and engagement with investigator sites and patients to reduce overall time and costs that come with drug development.

“Enrolling and engaging patients in clinical trials continues to be one of the biggest challenges within drug development. Our partnership with DuPage Medical Group extends our ability to help customers enhance clinical trial feasibility and improve patient enrollment timelines whilst also giving patients access to a broader range of care options through clinical trials,” said EB McLindon, senior VP of site and patient recruitment at Icon, in a press release. “We are committed to enhancing engagement with sites, patients and healthcare providers to take significant time and cost from our customers’ development programs.”

As a multi-specialty physician group in Chicago, DuPage Medical will help bring investigator and patient access to the Chicago area, as well as clinical research as a care option.

“Through this collaboration, additional communities in Illinois, along with more of DuPage Medical Group’s patients, will have increased access to clinical research in a broad range of therapeutic areas,” said Paul Merrick, president of DuPage Medical. “The integration of clinical research into patient care as a result of partnerships between healthcare institutions and clinical research site organisations delivers additional benefits and innovative solutions to the drug development process; both patients and healthcare providers will ultimately see lowered costs and faster time to market for potentially life-saving medications, vaccines, and medical devices.”



Source link

Leave a Reply

Your email address will not be published.